Dear Reader,
This exciting new NASDAQ company trading at just under $5 that has caught our attention.
With its main early cancer detection product already approved and marketed in the EU, it's only a matter of time before the FDA gives the green light for availability in the US.
In fact, the company's biggest competitor experienced exponential growth after FDA approval in 2014, increasing its market cap from $400 million to nearly $12 billion.
This shows the incredible potential of FDA approval for pharmaceutical companies.
It's not just us who are excited about this opportunity, top analysts from HC Wainwright, JonesTrading, and Cantor Fitzgerald have all given this company a buy or overweight rating.
This is a clear sign that the company is poised for success.
Believe me when I tell you that you don't want to sleep on this stock.
Do your research and click here to get the name and symbol right now.
_______________________________________________________________________
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
No comments:
Post a Comment